Xcout IntelSign inSubscribe

Psylo, Inc.

BiotechnologyAustralia

Psylo, Inc. is a biotechnology company focused on the discovery and development of next-generation neuroplastogens to treat psychiatric and neurological conditions. The company leverages medicinal chemistry and pharmacology to engineer safer, non-hallucinogenic psychedelic-inspired therapeutics. Its research and drug development efforts primarily serve patients suffering from treatment-resistant mental health disorders.

Subscribe to see Psylo, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Psylo, Inc. at a glance

Psylo, Inc. is a biotechnology company headquartered in Australia. Its most recent funding round raised $5M in May 2024. Xcout tracks 10 named people at Psylo, Inc., including Joshua Ismin (Chief Executive Officer, Cofounder).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotechnology
Headquarters
Australia

Psylo, Inc. leadership

  • Joshua IsminChief Executive Officer, Cofounder
  • Lisa VelardoChief Financial Officer
  • Dr. Sam BanisterChief Scientific Officer, Cofounder
  • Dr. Bradley JoblinVice President of Clinical Readiness
  • Dr. Donald GehlertVice President of Translational Biology
  • Dr. Jianmin DuanVice President of Pharmacology DMPK

4 more named people on record for Psylo, Inc., with roles, board committees and tenure — see the full roster →

Psylo, Inc. funding rounds

Every round on record:

DateRoundAmountInvestors
SEC Form D filing$5M—
Seed$8M5 named
Seed$1.1M3 named

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Who funded each Psylo, Inc. round

A funding-flow diagram of the 8 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.

Sign in to see it, or subscribe for the full funding history →

Investors

Psylo, Inc. competitors

A few of Psylo, Inc.'s closest competitors — see the full list of competitors and alternatives →

Alto Neuroscience, Inc.ANRO · BiotechMountain View, CA, United States
72% matchPublic

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Market cap$1.2B
Employees76
Alto Neuroscience, Inc. competitors & alternatives →

Get Psylo, Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Psylo, Inc.? Suggest a correction · Work at Psylo, Inc.? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Psylo, Inc. on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Psylo, Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Psylo, Inc. in Xcout Intel

  • 10 named people with titles, LinkedIn and board committees
  • 3 funding rounds with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →